Gelteq Limited
GELSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeGelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. The $4.6M market capitalization puts GELS squarely in micro-cap range for its industry. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.
Market Cap
$4.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.44
EPS (Fwd)
—
ROE
-42.9%
ROA
-17.6%
Cash
$9,349
Total Debt
$5.1M
Free CF
-$4.8M
52W Change
-64.5%
Annual Financials
Cash vs Debt
Where GELS stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, GELS finished 30.65% below its 150-day moving average ($0.62) and 36.76% below its 200-day moving average ($0.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GELS overbought or oversold?
At the October 16, 2026 close, GELS's RSI(14) was 28.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $9K in cash, though total debt stands at $5.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$4.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -42.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $148K to $166K.
Gelteq Limited carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Gelteq Limited and its sector.